Beyond GvHD, multiple trials have assessed or are actively investigating the safety and efficacy of polyclonal FOXP3+ Treg cell therapy in various autoimmune disease settings, including type 1 diabetes (NCT02691247) (140–143), lupus (144), multiple sclerosis (145), Crohn’s (146, 147), and Pemphigus vulgaris (NCT03239470), among others. Here, FOXP3 is linked to type 1 diabetes mellitus.